MX2023006193A - Compuesto triciclico fusionado, metodo de preparacion y aplicacion del mismo en medicina. - Google Patents
Compuesto triciclico fusionado, metodo de preparacion y aplicacion del mismo en medicina.Info
- Publication number
- MX2023006193A MX2023006193A MX2023006193A MX2023006193A MX2023006193A MX 2023006193 A MX2023006193 A MX 2023006193A MX 2023006193 A MX2023006193 A MX 2023006193A MX 2023006193 A MX2023006193 A MX 2023006193A MX 2023006193 A MX2023006193 A MX 2023006193A
- Authority
- MX
- Mexico
- Prior art keywords
- preparation
- method therefor
- fused tricyclic
- medicine
- tricyclic compound
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 239000003814 drug Substances 0.000 title abstract 4
- 238000002360 preparation method Methods 0.000 title abstract 3
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 abstract 1
- 102100039390 Toll-like receptor 7 Human genes 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente invención se refiere a un compuesto tricíclico fusionado, un método de preparación del mismo y una aplicación del mismo en medicina. Específicamente, la presente invención se relaciona con un compuesto tricíclico condensado representado por la Formula general (I), un método de preparación del mismo, una composición farmacéutica que contiene el compuesto y su uso como agente terapéutico, particularmente un uso como inhibidor TLR7/8/9 y un uso en la preparación de un fármaco para el tratamiento y/o prevención de enfermedades inflamatorias y autoinmunes. La definición de cada grupo en la Formula general (I) es como se define en la descripción. (ver Fórmula).
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011346809 | 2020-11-26 | ||
| CN202110074443 | 2021-01-20 | ||
| CN202110401565 | 2021-04-14 | ||
| CN202111128775 | 2021-09-26 | ||
| PCT/CN2021/133540 WO2022111636A1 (zh) | 2020-11-26 | 2021-11-26 | 稠合三环化合物、其制备方法及其在医药上的应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023006193A true MX2023006193A (es) | 2023-06-09 |
Family
ID=81753993
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023006193A MX2023006193A (es) | 2020-11-26 | 2021-11-26 | Compuesto triciclico fusionado, metodo de preparacion y aplicacion del mismo en medicina. |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP4253387A4 (es) |
| JP (1) | JP2023550793A (es) |
| KR (1) | KR20230113569A (es) |
| CN (1) | CN116490506A (es) |
| AU (1) | AU2021385752A1 (es) |
| CA (1) | CA3200155A1 (es) |
| MX (1) | MX2023006193A (es) |
| TW (1) | TW202227442A (es) |
| WO (1) | WO2022111636A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL307203A (en) | 2021-04-16 | 2023-11-01 | Gilead Sciences Inc | THIENOPYRROLE COMPOUNDS |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101384593A (zh) * | 2006-02-17 | 2009-03-11 | 辉瑞有限公司 | 用作tlr7调节剂的3-脱氮嘌呤衍生物 |
| CA2840060A1 (en) | 2011-06-27 | 2013-01-03 | Kyorin Pharmaceutical Co., Ltd. | Bridged bicyclic compounds for the treatment of bacterial infections |
| CN105367576A (zh) * | 2014-08-15 | 2016-03-02 | 正大天晴药业集团股份有限公司 | 作为tlr7激动剂的吡咯并嘧啶化合物 |
| WO2017106607A1 (en) | 2015-12-17 | 2017-06-22 | Merck Patent Gmbh | Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders |
| US10071079B2 (en) | 2016-06-29 | 2018-09-11 | Bristol-Myers Squibb Company | [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds |
| US10660877B2 (en) | 2016-09-09 | 2020-05-26 | Bristol-Myers Squibb Company | Pyridyl substituted indole compounds |
| EP3573974A1 (en) | 2017-01-27 | 2019-12-04 | Genfit | Rorgamma modulators and uses thereof |
| EP3636646A4 (en) * | 2017-05-18 | 2020-12-09 | Jiangsu Hengrui Medicine Co., Ltd. | HETEROARYL PYRAZOL DERIVATIVE AND MANUFACTURING METHOD FOR IT AND MEDICAL USES THEREOF |
| CN108948016B (zh) * | 2017-05-19 | 2021-02-26 | 江苏恒瑞医药股份有限公司 | 嘌呤酮类衍生物、其制备方法及其在医药上的应用 |
| DK3728252T3 (da) * | 2017-12-18 | 2023-11-13 | Bristol Myers Squibb Co | 4-azaindolforbindelser |
| KR20210018818A (ko) * | 2018-06-05 | 2021-02-18 | 에프. 호프만-라 로슈 아게 | 자가면역 질환의 치료를 위한 테트라하이드로-1H-피라지노[2,1-a]이소인돌릴퀴놀린 화합물 |
| WO2020020800A1 (en) | 2018-07-23 | 2020-01-30 | F. Hoffmann-La Roche Ag | Novel piperazine compounds for the treatment of autoimmune disease |
| CN112673003A (zh) | 2018-09-07 | 2021-04-16 | 豪夫迈·罗氏有限公司 | 用于治疗自身免疫性疾病的新型吡咯烷胺化合物 |
| TW202214632A (zh) * | 2020-07-27 | 2022-04-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | 吲哚稠環類衍生物、其製備方法及其在醫藥上的應用 |
-
2021
- 2021-11-26 JP JP2023531617A patent/JP2023550793A/ja active Pending
- 2021-11-26 WO PCT/CN2021/133540 patent/WO2022111636A1/zh active Application Filing
- 2021-11-26 TW TW110144251A patent/TW202227442A/zh unknown
- 2021-11-26 CA CA3200155A patent/CA3200155A1/en active Pending
- 2021-11-26 MX MX2023006193A patent/MX2023006193A/es unknown
- 2021-11-26 AU AU2021385752A patent/AU2021385752A1/en active Pending
- 2021-11-26 KR KR1020237020368A patent/KR20230113569A/ko unknown
- 2021-11-26 CN CN202180071880.XA patent/CN116490506A/zh active Pending
- 2021-11-26 EP EP21897136.4A patent/EP4253387A4/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3200155A1 (en) | 2022-06-02 |
| WO2022111636A1 (zh) | 2022-06-02 |
| TW202227442A (zh) | 2022-07-16 |
| EP4253387A1 (en) | 2023-10-04 |
| JP2023550793A (ja) | 2023-12-05 |
| EP4253387A4 (en) | 2024-05-15 |
| CN116490506A (zh) | 2023-07-25 |
| AU2021385752A1 (en) | 2023-06-29 |
| KR20230113569A (ko) | 2023-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20200488A (es) | Péptidos macrocíclicos contra actinetobacter baumannii | |
| MX2021006421A (es) | Anilidas de aminoácidos como moduladores de moléculas pequeñas de interleucinas-17 (il-17). | |
| MX368504B (es) | Derivados de amidas y sales farmaceuticamente aceptables de los mismos, método de preparación de los mismos y aplicación médica de los mismos. | |
| MX2022010520A (es) | Macrociclos peptidicos contra acinetobacter baumannii. | |
| MX2022008066A (es) | Compuestos triciclicos sustituidos. | |
| MX2022006475A (es) | Compuestos triciclicos sustituidos. | |
| CR20210563A (es) | Compuestos y métodos para el tratamiento de covid-19 | |
| MX356411B (es) | Derivados del tipo del azaindazol o diazaindazol como medicamento. | |
| MX2019011491A (es) | Formulaciones de niraparib. | |
| HUP0302474A2 (hu) | Terápiásan hatásos tropánszármazékok, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| MX2023007853A (es) | Compuesto heterociclico puenteado que contiene nitrogeno, metodo de preparacion y uso medico del mismo. | |
| MX2021010106A (es) | Inhibidores de la via de respuesta al estres integrada. | |
| MX2022005985A (es) | Derivado de pirazolo-heteroarilo, metodo de preparacion y uso medico del mismo. | |
| MX2022015531A (es) | Derivado de piridina-pirimidina, metodo de preparacion y uso farmaceutico del mismo. | |
| TNSN04048A1 (en) | Dosage regimen and pharmaceutical composition for emergency contraception | |
| MX2021006724A (es) | Compuestos de halo-alilamina y uso de los mismos. | |
| MX2022015554A (es) | Moduladores de molecula peque?a de interleucina 17 (il-17). | |
| ZA200300828B (en) | New aporphine esters and their use in therapy. | |
| MX2023006504A (es) | Compuesto de hidroxamato, metodo de preparacion del mismo y aplicacion del mismo. | |
| MX2022015886A (es) | Derivados de amidopirimidona. | |
| MX2022013273A (es) | Compuestos y composiciones para inhibir la actividad de hif2-alfa y sus metodos de uso. | |
| MX2023006193A (es) | Compuesto triciclico fusionado, metodo de preparacion y aplicacion del mismo en medicina. | |
| MX2019007213A (es) | Derivado de azaciclobutil triazol del grupo anular condensado, metodo de preparacion del mismo y uso del mismo en medicina. | |
| MX2020013692A (es) | Compuestos de pirazol e imidazol para la inhibicion de il-17 y rorgamma. | |
| MX2022010402A (es) | Compuestos derivados de 1,3,4-oxadiazol como inhibidores de histona desacetilasa 6, y la composicion farmaceutica que comprende los mismos. |